We are live on ! Find out more
IBT

International Biotechnology Trust Portfolio holdings

AUM $297M Turnover 20%
1-Year Est. Return 17.25%
This Fund
S&P 500
This Quarter Est. Return
+4.48%
1 Year Est. Return
+17.25%
3 Year Est. Return
+11.14%
5 Year Est. Return
+79.35%
10 Year Est. Return
–
AUM
$329M
AUM Growth
-$29.9M
Cap. Flow
-$29.1M
Cap. Flow %
-8.87%
Top 10 Hldgs %
51.54%
Holding
77
New
13
Increased
17
Reduced
12
Closed
16
Avg Time Held
1.7 years
Top 10 Avg Time Held
0.4 years
Top 20 Avg Time Held
0.5 years

Top Buys

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$12.2M
2
APLS icon
Apellis Pharmaceuticals
APLS
+$8.46M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$7.07M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$6.94M
5
GILD icon
Gilead Sciences
GILD
+$6.94M

Top Sells

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$40.5M
2
ALKS icon
Alkermes
ALKS
+$16.7M
3
EXEL icon
Exelixis
EXEL
+$10.5M
4
QURE icon
uniQure
QURE
+$8.77M
5
RARE icon
Ultragenyx Pharmaceutical
RARE
+$8.53M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
AMGN icon
1
Amgen
AMGN
$235B
$26M 7.92%
117,246
+26,000
+28% +$6.03M
2018 Q4
18 quarters
INCY icon
2
Incyte
INCY
$23B
$22.3M 6.79%
358,454
+79,454
+28% +$5.31M
2016 Q4
26 quarters
HRMY icon
3
Harmony Biosciences
HRMY
$2.23B
$20.1M 6.11%
570,500
– –
2021 Q2
8 quarters
REGN icon
4
Regeneron Pharmaceuticals
REGN
$82B
$19.4M 5.91%
27,000
+15,800
+141% +$12.2M
2020 Q2
12 quarters
SUPN icon
5
Supernus Pharmaceuticals
SUPN
$2.3B
$15.7M 4.79%
523,500
+100,000
+24% +$3.5M
2021 Q2
8 quarters
VERA icon
6
Vera Therapeutics
VERA
$2.06B
$15.6M 4.76%
975,227
-27,030
-3% -$244K
2021 Q4
6 quarters
ALNY icon
7
Alnylam Pharmaceuticals
ALNY
$31.3B
$15.5M 4.72%
81,600
+35,000
+75% +$6.94M
2017 Q3
23 quarters
APLS icon
8
DELISTED
Apellis Pharmaceuticals
APLS
$11.8M 3.6%
129,700
+98,000
+309% +$8.46M
2022 Q4
2 quarters
UTHR icon
9
United Therapeutics
UTHR
$23.2B
$11.6M 3.55%
52,759
+24,259
+85% +$5.37M
2022 Q1
5 quarters
ITCI icon
10
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$11.2M 3.4%
176,856
-81,000
-31% -$5.05M
2020 Q1
13 quarters
GILD icon
11
Gilead Sciences
GILD
$195B
$11.1M 3.39%
144,584
+87,000
+151% +$6.94M
2016 Q4
26 quarters
ILMN icon
12
Illumina
ILMN
$40.5B
$9.46M 2.88%
51,914
+24,672
+91% +$4.99M
2021 Q3
7 quarters
MRTX
13
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$9.39M 2.86%
260,000
+16,000
+7% +$659K
2019 Q1
17 quarters
VRTX icon
14
Vertex Pharmaceuticals
VRTX
$129B
$7.39M 2.25%
21,000
-12,000
-36% -$4.04M
2023 Q1
1 quarter
RVNC icon
15
DELISTED
Revance Therapeutics, Inc.
RVNC
$7.3M 2.22%
288,726
+105,726
+58% +$3.29M
2022 Q3
3 quarters
HZNP
16
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$6.89M 2.1%
+67,000
New +$7.07M
2023 Q2
0 quarters
TVTX icon
17
Travere Therapeutics
TVTX
$4.98B
$6.77M 2.06%
441,019
+300,000
+213% +$5.46M
2020 Q4
10 quarters
NBIX icon
18
Neurocrine Biosciences
NBIX
$13.9B
$6.49M 1.98%
+68,877
New +$6.73M
2023 Q2
0 quarters
KRTX icon
19
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$5.57M 1.69%
25,700
+14,700
+134% +$3.15M
2023 Q1
1 quarter
AUPH icon
20
Aurinia Pharmaceuticals
AUPH
$2.23B
$5.55M 1.69%
573,530
– –
2020 Q3
11 quarters
DNLI icon
21
Denali Therapeutics
DNLI
$2.93B
$5.54M 1.69%
188,000
+101,425
+117% +$2.85M
2021 Q4
6 quarters
KRYS icon
22
Krystal Biotech
KRYS
$9.77B
$5.39M 1.64%
45,945
-15,055
-25% -$1.54M
2021 Q4
6 quarters
BMRN icon
23
BioMarin Pharmaceuticals
BMRN
$10.8B
$5.08M 1.55%
58,656
– –
2016 Q4
26 quarters
MDGL icon
24
Madrigal Pharmaceuticals
MDGL
$10.6B
$4.23M 1.29%
+18,300
New +$4.96M
2023 Q2
0 quarters
AXSM icon
25
Axsome Therapeutics
AXSM
$8.47B
$4.19M 1.27%
+58,300
New +$4.3M
2023 Q2
0 quarters
1
2 3 4

Similar funds

DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
DT
Daniels + Tansey Wilmington, Delaware $289M AUM 18.06% 1-Year Est. Return
3LCM
3D/L Capital Management Hartford, Connecticut $308M AUM 13.67% 1-Year Est. Return
TFA
Triad Financial Advisors Greensboro, North Carolina $284M AUM 14.95% 1-Year Est. Return
SFG
Steward Financial Group Colleyville, Texas $315M AUM 13.78% 1-Year Est. Return
AEPLI
AH Equity Partners LSV I Menlo Park, California $315M AUM 9.31% 1-Year Est. Return
CC
Chanos & Company New York $318M AUM 4.62% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

International Biotechnology Trust's Q2 2023 Portfolio in Review

As of Q2 2023, International Biotechnology Trust held 77 positions worth $329M, down 8.3% from $358M the previous quarter. Its ten largest holdings account for 52% of the portfolio.

International Biotechnology Trust withdrew a net $29.1M in Q2 2023, closing 16 positions and reducing 12 holdings. Its most notable exit was Seagen Inc. Common Stock, an estimated $40.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

Against the trend, International Biotechnology Trust opened a new position in Horizon Therapeutics Public Limited Company Ordinary Shares worth $6.89M.

  • International Biotechnology Trust's largest Q2 2023 buy was Horizon Therapeutics Public Limited Company Ordinary Shares: 67,000 shares worth $6.89M.
  • International Biotechnology Trust added most to Regeneron Pharmaceuticals in Q2 2023, an estimated $12.2M increase.
  • International Biotechnology Trust's biggest Q2 2023 reduction was uniQure, cutting an estimated $8.77M.
  • International Biotechnology Trust fully exited Seagen Inc. Common Stock in Q2 2023, selling an estimated $40.5M.
  • International Biotechnology Trust's ten largest holdings make up 52% of its $329M portfolio in Q2 2023.
  • International Biotechnology Trust opened 13 new positions and closed 16 in Q2 2023.
  • International Biotechnology Trust's portfolio value fell 8.3% quarter-over-quarter to $329M.

Based on International Biotechnology Trust's 13F filing for Q2 2023, filed 8 Aug 2023.